### GEOFFREY L. ROSENTHAL, M.D., Ph.D. January 5, 2016

	Page 1			Page 3
1	UNITED STATES PATENT AND TRADEMARK OFFICE	1	INDEX	
2	BEFORE THE PATENT TRIAL AND APPEAL BOARD	2	Deposition of GEOFFREY L. ROSENTHAL, M.D.,	Ph.D.
3		3	<b>January 5, 2016</b>	
4	PRAXAIR DISTRIBUTION, INC.	4		
5	Petitioner	5	Examination By:	Page
6	v.	6	Ms. Kerrane	4
7	INO THERAPEUTICS, LLC,	7	Mr. Schuler	160
8	Patent Owner	8		
9	Case IPR2015-00529	9		
10	U.S. Patent No. 8,846,112 B2	10		
11		11		
12	The deposition of GEOFFREY L. ROSENTHAL,	12		
13	M.D., Ph.D., was held on Tuesday, January 5, 2016,	13		
14	commencing at 9:30 a.m., at the Law Offices of Latham	14		
15	and Watkins, 555 Eleventh Street, N.W., Suite 1000,	15		
16	Washington, D.C. 20004, before Steven Poulakos, RPR,	16		
17	Notary Public.	17		
18		18		
19		19		
20		20		
21		21		
22		22		
23		23		
24		24		
25	REPORTED BY: Steven Poulakos, RPR	25		
	Page 2			Page 4
1	APPEARANCES :	1	PROCEEDINGS	
2		2		
3	ON BEHALF OF PRAXAIR DISTRIBUTION, INC.	3		
4	SARA N. KERRANE, ESQUIRE	4	Whereupon,	
5	K&L Gates			
6		5	GEOFFREY L. ROSENTHAL, M.D., Ph.D.,	
•	One Park Plaza	5 6	GEOFFREY L. ROSENTHAL, M.D., Ph.D., called as a witness, having been first duly sworn to	
7	One Park Plaza Twelfth Floor			
7 8		6	called as a witness, having been first duly sworn to	
7	Twelfth Floor	6 7	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the	
7 8 9 10	Twelfth Floor Irvine, California 92614	6 7 8	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows:	
7 8 9 10 11	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com	6 7 8 9	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham &	
7 8 9 10 11 12	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC:	6 7 8 9 10 11 12	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc.	
7 8 9 10 11 12 13	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE	6 7 8 9 10 11	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham	
7 8 9 10 11 12 13 14	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE	6 7 8 9 10 11 12 13 14	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent.	
7 8 9 10 11 12 13 14 15	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP	6 7 8 9 10 11 12 13 14 15	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of	
7 8 9 10 11 12 13 14 15 16	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue	6 7 8 9 10 11 12 13 14 15 16	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt.	
7 8 9 10 11 12 13 14 15 16 17	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800	6 7 8 9 10 11 12 13 14 15 16 17	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt. EXAMINATION BY MS. KERRANE	
7 8 9 10 11 12 13 14 15 16 17 18	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611	6 7 8 9 10 11 12 13 14 15 16 17 18	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt. EXAMINATION BY MS. KERRANE Q Good morning, Dr. Rosenthal.	
7 8 9 10 11 12 13 14 15 16 17 18 19	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Telephone: 312.876.7700	6 7 8 9 10 11 12 13 14 15 16 17 18 19	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt. EXAMINATION BY MS. KERRANE Q Good morning, Dr. Rosenthal. A Good morning.	
7 8 9 10 11 12 13 14 15 16 17 18 19 20	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Telephone: 312.876.7700 Email: Kenneth.schuler@lw.com	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt. EXAMINATION BY MS. KERRANE Q Good morning, Dr. Rosenthal. A Good morning. Q Could you please state your full name for	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Telephone: 312.876.7700	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	<ul> <li>called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows:</li> <li>MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc.</li> <li>MR. SCHULER: Ken Schuler from Latham &amp; Watkins, on behalf of the witness and the respondent.</li> <li>MR. ZUBICK: Marc Zubick, also with Latham &amp; Watkins, on behalf of the witness and respondent.</li> <li>MR. GOETZ: Ken Goetz on behalf of Mallinckrodt.</li> <li>EXAMINATION BY MS. KERRANE</li> <li>Q Good morning, Dr. Rosenthal.</li> <li>A Good morning.</li> <li>Q Could you please state your full name for the record?</li> </ul>	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Telephone: 312.876.7700 Email: Kenneth.schuler@lw.com	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt. EXAMINATION BY MS. KERRANE Q Good morning, Dr. Rosenthal. A Good morning. Q Could you please state your full name for the record? A My name is Jeffrey Lynn Rosenthal.	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Telephone: 312.876.7700 Email: Kenneth.schuler@lw.com	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<ul> <li>called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows:</li> <li>MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc.</li> <li>MR. SCHULER: Ken Schuler from Latham &amp; Watkins, on behalf of the witness and the respondent.</li> <li>MR. ZUBICK: Marc Zubick, also with Latham &amp; Watkins, on behalf of the witness and respondent.</li> <li>MR. GOETZ: Ken Goetz on behalf of Mallinckrodt.</li> <li>EXAMINATION BY MS. KERRANE</li> <li>Q Good morning, Dr. Rosenthal.</li> <li>A Good morning.</li> <li>Q Could you please state your full name for the record?</li> <li>A My name is Jeffrey Lynn Rosenthal.</li> <li>Q Could you please state your address for the</li> </ul>	
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Twelfth Floor Irvine, California 92614 Telephone: 949.253.0900 Email: Sara.kerrane@klgates.com ON BEHALF OF INO PHARMACEUTICALS, LLC: KENNETH G. SCHULER, ESQUIRE MARC ZUBICK, ESQUIRE Latham & Watkins, LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Telephone: 312.876.7700 Email: Kenneth.schuler@lw.com	6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	called as a witness, having been first duly sworn to tell the truth, the whole truth, and nothing but the truth, was examined and testified as follows: MS. KERRANE: Sara Kerrane on behalf of Petitioners, Praxair Distribution, Inc. MR. SCHULER: Ken Schuler from Latham & Watkins, on behalf of the witness and the respondent. MR. ZUBICK: Marc Zubick, also with Latham & Watkins, on behalf of the witness and respondent. MR. GOETZ: Ken Goetz on behalf of Mallinckrodt. EXAMINATION BY MS. KERRANE Q Good morning, Dr. Rosenthal. A Good morning. Q Could you please state your full name for the record? A My name is Jeffrey Lynn Rosenthal.	

INO	THERAPEUTICS, LLC.		January	5, 2016
	,	Page 5	•	Page 7
1	Maryland.	1	is pertains to this particular deposition, I can ask	
2	Q Thank you.	2		
3	Have you ever been deposed before,	3		
4	Dr Rosenthal?	4		
5	A I have been deposed previously.	5		
6	Q And what circumstances was that?	6		
7	A I was deposed in a case related to a	7	Q Okay. Great.	
8	hostile work environment charge.	8	-	
9	Q Okay. And other than that incident, have	9		
10	you ever been deposed?	10	-	
11	A That's the only deposition that I've had.	11	Q And is there any medications or anything	
12	Q Have you ever testified at trial?	12		
13	A I have testified at trial once previously.	13		
14	Q Okay. And what were the circumstances for	14	Q Now, have you ever provided a report or a	
15	that?	15		
16	A I was an expert witness. I was the	16		
17	treating physician in a sexual assault case.	17	Q Okay. And have you ever been a consultant	
18	Q And what aspects of medicine were you if	18		
19	you can, what aspects of medicine were you providing	19		
20	expert testimony on?	20		
21	A I was asked to review the medical	21		
22	documentation from an emergency room visit for the	22		
23	subject, for the patient, and testify as to my physical	23		
24	exam findings.	24		
25	Q And other than those two experiences, have	25		
		Page 6		Page 8
1	you ever been asked to provide live testimony in any	1	THE WITNESS: Thank you.	
2	circumstances?	2	I have provided expert review in medical	
3	A I have not.	3		
4	Q I'm going to go over a few ground rules	4		
5	with you, which you may already be familiar with.	5	Q Okay. And have those been in conjunction	
6	First, obviously, I'm going to be asking	6		
7	you a series of questions. If you could please wait	7	-	
8	until my question is done before you provide the	8	provide expert review by attorneys representing one	
9	answer. Also, if you could please make sure your	9		
10	answers are all verbal answers so the court reporter is	10	Q And have you ever been involved in a patent	
11	able to write them down. If there's any questions that	11		
12	you don't understand, please let me know so that I can	12	-	
13	make sure to rephrase them for you and so that we can	13		
14	make sure that the answers you're providing are	14		
15	truthful answers and accurate.	15		
16	If you need a break at any time, please let	16		
17	me know, and we can do that, but I ask that you first	17		
18	answer any pending questions that may be presented	18		
19	before you request a break.	19		
20	Do you have any questions?	20		
21	A I don't. I understand what you've just	21		
22	said.	21		
23	Q Great.	22		
23		23		

23 Q Oreat.
24 And, also, do you understand that on any of
25 the breaks, if you discuss any subject matter that

**R** M

D

Α

O

A

Find authenticated court documents without watermarks at docketalarm.com.

24

25

Α

Q

Yes, I had.

And in what circumstances did you read a

**25** declaration with counsel.

NO	THERAPEUTICS, LLC.		January 5, 20
	Page 9		Page 1
1	patent?	1	BY MS. KERRANE:
2	A I have read a number of patents previously,	2	Q How many days did you meet with your
3	related to invention interests of people in my family	3	counsel?
4	and some related to colleagues at work.	4	A I don't know the exact number of days that
5	Q Are you a named inventor on any patents?	5	I met with counsel. A handful of times, perhaps.
6	A I am not.	6	Q All in preparation for this deposition?
7	Q When were you first retained for this	7	A In one way or another, yes, all in
8	matter?	8	preparation for the deposition.
9	A I was first retained perhaps 11, 10 or 11	9	Q What attorneys did you meet with?
0	months ago.	10	A I primarily met with Marc Zubick.
1	Q Okay.	11	Q And how long would you say you spent
2	A By the law firm Fitzpatrick.	12	preparing for this deposition?
3	Q And do you recall who contacted you?	13	A Roughly 200 hours, perhaps, in terms if
4	MR. SCHULER: And let me counsel you that	14	we include review of documents and other information
5	whenever you're answering questions about contact with	15	that's relevant to the declaration.
6	attorneys for carrying a	16	Q Does that include the time you spent
7	(Reporter clarifies.)	17	preparing the declaration?
, 8	<b>MR. SCHULER:</b> You can identify the person,	18	A Yes, it does.
9		19	•
	et cetera, but don't divulge the contents of any		Q And how long did you spend specifically
0	communications.	20	after submitting the declaration and preparing for just
1	<b>THE WITNESS:</b> Okay. So the person who I	21	the deposition?
2	spoke most frequently with was Melinda Roberts.	22	A I'm not sure exactly. Maybe half that
3	BY MS. KERRANE:	23	time. So maybe a hundred hours.
4 5	Q Okay. And do you understand why you're here today?	24 25	Q Did you discuss the deposition with anyone other than your attorneys?
	Page 10		Page 2
1	A Yes, I do.	1	A No, I've not.
2	Q I see in front of you, you have what looks	2	Q Did you review any documents while
3	like a copy of your declaration that you provided in	3	preparing for your deposition?
4	this case; is that correct?	4	A Yes, I did.
5	A Yes, that's correct.	5	Q Other than your report, do you recall what
6	Q And is that something that you just walked	6	documents you reviewed?
7	in with?	7	MR. SCHULER: Object to the form.
8	A Yes, I just walked in with it.	8	You mean his declaration?
9	Q Do you have any notations on that?	9	MS. KERRANE: I'm sorry, declaration.
0	A I have no notations on this document.	10	THE WITNESS: I believe the answer to
1	Q But I see that you've folded some pages	11	your question is, yes, I have reviewed other documents
2	over.	12	in addition to the declaration, and those things that
3	A I folded pages over that correspond to the	13	I've reviewed appear in paragraph 16 in my declaration.
4	major headings in the table of contents.	14	BY MS. KERRANE:
5	Q Kind of as a road map for yourself?	15	Q Let's look at that paragraph real quick.
6	A Well, just to so I'm not fumbling	16	MR. SCHULER: You're just going to use
7	around.	17	Exhibit 2020.
8	Q What did you do to prepare for this	18	MS. KERRANE: They're the same exhibits,
9	deposition?	19	yes.
0	MR. SCHULER: And, again, you can describe	20	BY MS. KERRANE:
1	actions you took, but don't divulge the contents or	21	Q Exhibit 2020 is your declaration, correct?
2	communications with anyone.	22	A Yes, that's the label on the bottom right
3	THE WITNESS: I reviewed information	23	corner of the document.
4	related to the patent, and I discussed elements of the	24	Q And I believe you referred to paragraph 16
5	declaration with counsel	25	in your report: is that correct?

**25** in your report; is that correct?

**DOCKET A L A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

	Pa	age 13	Page 1
1		-	proposed at the time you were proposing your
1 2	<ul><li>A Yes, that's correct.</li><li>Q So in this paragraph, I see that you</li></ul>	1	
3	mention that you've reviewed the claims of the '112	3	,
4	patent, file history, prior art exhibits that were part	4	5
5	of the petition, documents cited by Dr. Beghetti.	5	
5	Is there anything else?	6	5
7	MR. SCHULER: Objection. The document	7	
3	speaks for itself.	8	
)	<b>THE WITNESS:</b> I believe that paragraph 16	9	you have seen a final version of that document as it
)	correctly describes the documents that I reviewed.	10	) was filed with the PTAB?
L	BY MS. KERRANE:	11	A I believe that the version that I saw was a
2	Q Did you review Dr. Beghetti's declaration?	12	2 final version, yes.
3	A Yes, I did.	13	Q I see in paragraph 17, you mention that you
	Q Okay. And did you review the petition for	14	are being compensated for this proceeding; is that
	inter partes review for the '112 patent?	15	5 correct?
	A Yes, I did.	16	5 A That is correct.
,	Q Did you review either patent owner's	17	Q And do you own any shares in Ikaria?
	preliminary response or its response in this	18	B A I do not.
)	proceeding?	19	Q In Mallinckrodt?
)	MR. SCHULER: Object to form.	20	) A I do not.
L	<b>THE WITNESS:</b> Can you help me by	21	Q Or INO Therapeutics?
2	distinguishing between the either/ors? I did review	22	-
3	the I did review the PTAB decision institute, IPR.	23	_
1	Is that what you were asking?	24	
5	BY MS. KERRANE:	25	
	Pa	age 14	Page
•	Q No, but that was my next question.	1	
	So you did review the decision to	2	2 you have any relationship with Ikaria?
	institute, correct?	3	
	A Correct.	4	Q Okay. Were you using products from Ikaria?
	Q And the patent owner, which would be INO	5	A Yes. I have used inhaled nitric oxide in
	Therapeutics, also submitted two documents.	6	5 my clinical practice.
	Did you review either of those two	7	Q Has Ikaria ever provided you with grants?
	documents?	8	B A It has not.
	A It's not clear to me which documents you're	9	Q Has Ikaria ever hired you or asked you to
)	referring.	10	
-	Q Did you review any documents submitted by	11	
2	patent owner in this proceeding?	12	-
	A I have, yes.	13	
	Q And do you recall when you did that?	14	
;	A It would have been in early November.	15	
;	Q And do you know if you have seen a final	16	
	A AND GO YOU KNOW IT YOU HAVE SEEN A HILAI	10	

Q And do you know if you have seen a final 16 17 version of that document as it was filed with the PTAB? MR. SCHULER: Object to the form. 18 THE WITNESS: Again, the document to which 19 20 you are referring is which? 21 **BY MS. KERRANE:** 22 Q You mentioned that you looked at a document 23 in early November; is that correct. 24 А Yes.

And is that a document that was being

#### 

Q

25

Find authenticated court documents without watermarks at docketalarm.com.

17

18

19

20

21

22

23

24

25

Q

А

Q

Mallinckrodt?

I have not.

And prior to this proceeding, did you have

Have you ever been involved in any studies

THE WITNESS: Could you be more specific

any relationships with Mallinckrodt Pharmaceuticals?

that were sponsored by Ikaria, INO Therapeutics, or

MR. SCHULER: Object to the form.

about what you mean by having been involved?

DOCKET

	Page 17			Page 19
1	BY MS. KERRANE:	1	than those listed in paragraph 16, or referred to in	
2 3	Q Okay. What does that mean to you?	2	paragraph 16?	
	A Well, the reason I asked the question is	3	MR. SCHULER: Object to the form.	
4	because I'm not there are a number of different possible meanings for that, and I'm trying to understand your question.	4 5	THE WITNESS: Can you be more specific in	
5 6			terms of your question, because the reason I'm asking	
		6	is I review a lot of publications in my role as a	
7	Q Okay. Have you been have you	7	physician. I think specifically, you must be asking	
8	participated in any studies sponsored by Ikaria, INO	8	about a certain type of publication.	
9	Therapeutics, or Mallinckrodt?	9	Can you help me understand	
10	MR. SCHULER: Object to the form.	10	BY MS. KERRANE:	
11	THE WITNESS: May I ask you a question?	11	Q Sure.	
12	BY MS. KERRANE:	12	A your question?	
13	Q Sure.	13	Q Have you reviewed any publications that	
14	A Are you asking whether I've ever been a	14	relate to the subject matter at issue in this	
15	principal investigator for such a study, or are you	15	investigation or this inter partes review that are not	
16	asking some other question?	16	referred to in paragraph 16?	
17	Q I'm not limiting it to principal	17	MR. SCHULER: Can I have that one back.	
18	investigator, but a principal investigator or otherwise	18	(Whereupon the following portion of the testimony was	
19	participated in one of those such a study.	19	repeated by the Court Reporter:	
20	A So some of the studies that have taken	20	"QUESTION: Have you reviewed any	
21	place in clinical context have involved patients who	21	publications that relate to the subject matter at issue	
22	have been in my care. So I guess to the extent that	22 23 24	in this investigation or this inter partes review that are not referred to in paragraph 16?") <b>MR. SCHULER:</b> I'll object to the form.	
23	I've been involved in the care of patients who have			
24	been involved in studies, I've had involvement in the			
25	studies. But I've not specifically had involvement as	25	THE WITNESS: I don't think so.	
	Page 18			Page 20
1	a principal investigator in the study.	1	BY MS. KERRANE:	
2	O Okay At any time since being retained in	2	O If you can take a look at paragraph 1 of	

T	a principal investigator in the study.	1	DY MS. KERKANE:
2	Q Okay. At any time since being retained in	2	Q If you can take a look at paragraph 1 of
3	this matter, have you reviewed any information relating	3	your report.
4	to any other proceedings involving Praxair or Praxair	4	MS. KERRANE: Excuse me, your declaration.
5	distribution?	5	MR. SCHULER: That's all right. I was just
6	A No, I have not.	6	going to say, could we you understand that if she
7	Q Since submitting your declaration, have you	7	says "report," she actually means your declaration?
8	reviewed any materials that have not that are not	8	THE WITNESS: Yes.
9	listed in your report?	9	MR. SCHULER: Then I won't object anymore.
10	MR. SCHULER: Object to the form.	10	BY MS. KERRANE:
11	THE WITNESS: I don't believe so. I	11	Q And if you could, take a look at the last
12	believe all of the materials that I've reviewed would	12	sentence in there.
13	fall under the description in paragraph 16.	13	MR. SCHULER: And the reason she does that
14	BY MS. KERRANE:	14	is that most of the time, an expert gives a report in
15	Q And this declaration includes all of your	15	litigation. And this time, it's your written
16	opinions in this matter; is that correct?	16	testimony.
17	A That is correct.	17	THE WITNESS: The last sentence in
18	Q And as you sit here today, you have no	18	paragraph 1, you're directing me to?
19	different or new opinion, other than what you have	19	BY MS. KERRANE:
20	stated in this declaration, correct?	20	Q That's correct.
21	MR. SCHULER: Object to the form.	21	A (Witness reviewing document.)
22	THE WITNESS: No, I have no additional	22	Okay.
23	opinions, and these remain my opinions.	23	Q And my question to you is: What do you
24	BY MS. KERRANE:	24	mean by the term "neonate"?
25	Q Have you reviewed any publications other	25	A What I meant by the term "neonate" is an

**A L A R M** Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

## DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

### **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.